Clinipace Acquires German CRO Accovion

April 14, 2015
Philip Ward

Philip Ward is ACT's European editor, phone +44 1244 538583, philipward1@btconnect.com

Applied Clinical Trials

Clinipace Worldwide has announced the takeover of Accovion, a CRO with a head office in Frankfurt (Eschborn), Germany.

Clinipace Worldwide has announced the takeover of Accovion, a CRO with a head office in Frankfurt (Eschborn), Germany.

Accovion provides a range of clinical research services to the pharma, biotech and medical device sectors. It has operated for more than 10 years, and is active in more than 20 countries. Clinipace is seeking to broaden its operational and therapeutic expertise in Russia, Italy, Czech Republic, Romania, Poland, Spain, France and Ukraine.

Dr. Andree Beckerling, CEO of Accovion, will have day-to-day responsibility for all European offices, including existing Clinipace staff and locations. He will report to Clinipace CEO, Jeff Williams, and will join the company’s Executive Committee.

“To be competitive in today’s market, it is important to have, among other things, a strong multi-national scale, broad therapeutic expertise and a better service delivery model,” said Williams, CEO of Clinipace Worldwide. “Bringing our companies together substantially enhances our existing European footprint throughout Western, Central and Eastern Europe and enables us to offer a competitive array of global clinical development and regulatory services in these regions.”

Clinipace provides the right combination of complementary operational strengths, services and geography, according to Beckerling. Accovion’s clients gain access to Clinipace’s dCRO delivery model supported by their proprietary TEMPO eClinical platform and a comprehensive and integrated clinical operations, data management, biostatistics and regulatory consultancy with a large worldwide footprint, he added.

This is the sixth acquisition by Clinipace in the past few years, and it now has almost 1000 global staff. The combined company has managed over 3,000 clinical research studies and more than 300 regulatory and strategic development engagements, according to the announcement.
 

For the full press release, click here.